Board of Directors
Kevin Connors is an accomplished entrepreneur and venture investor. He has co-founded seven healthcare technology companies, and has had interim CEO roles in nine. These companies have focused on developing proprietary technology to address large un-met medical needs, such as emphysema, low back pain, cerebral aneurysm, and bladder dysfunction. Prior to founding Spray Venture Partners in 1996, Kevin was the founding CEO of Vesica Medical, a company focused on the surgical treatment of female urinary incontinence. Under this leadership, Vesica realized product sales within 18 months of formation and was acquired by Boston Scientific Corporation in 1995. Prior to Vesica, Kevin led medical device investment activity at DSV Partners in Newport Beach, California.
Kevin is on the Board of Directors of the New England Venture Capital Association and MassMEDIC, the Massachusetts Medical Device Industry Council. He has served on the Board of Directors of Vesica Medical, Inc. (acquired by Boston Scientific), Masimo Corp., Pilot Cardiovascular (acquired by CR Bard), Circe Biomedical (acquired by ICN Pharmaceuticals), Gamera Bioscience (acquired by Tecan AG), and Endonetics (acquired by Medtronic). In addition to serving on our board, he also serves on the boards of, Facet Solutions, Leptos Biomedical, Solace Therapeutics, Highgate Orthopedics, and Cascade Ophthalmics.
Kevin received a B.S. in Electrical Engineering from the University of Notre Dame, an M.S. in Electrical Engineering from the University of Dayton, and an M.B.A. from the Harvard Business School.
Jeani Delagardelle is a Managing Director and primarily concentrates on medical device efforts. Jeani joined Sprout in August 2000 and became General Partner in July 2001. Previously, she was a General Partner at Weiss, Peck & Greer Venture Partners where she focused on healthcare/technology investments. Before joining Weiss, Peck & Greer Venture Partners, Jeani spent 15 years in senior marketing, sales, business development and general manager positions in the healthcare industry. Specifically, she was Vice President of Global Marketing for Target Therapeutics (acquired by Boston Scientific for $1.1B) and spent nine years with the Medi-tech division of Boston Scientific in several senior management roles. In addition, Jeani served as Director of Business Operations for Roche Laboratories and Director of Global Marketing for Cell Pro, Inc. Jeani attended University of California at Irvine (MBA) and Occidental College (AB). Jeani leads the medical device investment effort.
Ryan joined NEA in 1996, and became a General Partner in 2004. He specializes in healthcare investments in the specialty pharma, medical device and healthcare information technology sectors. Present board memberships include BENU, Carticept Medical, Concentric Medical, Esprit Pharma, ExploraMed II, ForHealth Technologies, Intrinsic Therapeutics, PatientKeeper, Spine Wave, Viacor and Vibrynt. Past board memberships include ESP Pharma (acquired by Protein Design Labs, Inc.), FoxHollow Technologies (NASDAQ: FOXH), Provation Medical (acquired by Wolters Kluwer), and Proxima Therapeutics (acquired by Cytyc Corporation), and Ryan co-led NEA’s investment in Xcel Pharmaceuticals (acquired by Valeant Pharmaceuticals, Inc.).
Prior to joining NEA, Ryan was with the Health Care Investment Banking Group of Alex. Brown & Sons in San Francisco where he focused primarily on the medical device, biopharmaceutical and healthcare information technology areas. Previously, he worked in the San Francisco office of Arthur Andersen & Co. Ryan received a BA from Stanford University.
Prior to joining Intrinsic, Greg was a Vice President of Product Development & Marketing at Stryker, a global orthopedic implant company, where he directed the development and launch of numerous successful orthopedic implants. Greg also held various management positions in product and business development within Pfizer’s Medical Technology Group. The core of his career at Pfizer was implementing a process for inventing and developing new technologies that best met the needs of Pfizer’s physician customers worldwide.
Greg received a Bachelor of Science in Nuclear Engineering from the Massachusetts Institute of Technology in 1990 and returned to the same institution for a Masters Degree in Mechanical Engineering in 1993. He holds numerous patents in the fields of gynecology, general surgery, cardiology, and orthopedics.
Greg is also founder and board member of Viacor, Inc., a start-up medical device company in the Boston area.
Josh Makower, MD (Venture Partner)
Josh joined NEA in September 2004 as a Venture Partner. He works closely with NEA's healthcare team and focuses primarily on medical devices and pharmaceutical investments. Josh is also the Founder & Chief Executive Officer of ExploraMed II and III, Inc., both NEA portfolio companies created to be medical device incubators based on the West Coast. Acclarent, Inc. and NeoTract, Inc. have both been created by ExploraMed II and are launched and independently funded. In addition, Josh serves a part-time role on the faculty of the Stanford University Medical School as a Consulting Associate Professor of Medicine and is Co-Director of Stanford’s Biodesign Innovation Program.
Josh serves on the Board of Directors for Acclarent, Inc., NeoTract, Inc., ExploraMed II and III and Intrinsic Therapeutics, Inc. Prior to NEA, Josh was Founder, Chairman and Chief Technical Officer of TransVascular, Inc. (acquired by Medtronic, Inc. in 2003), and Founder and Chairman of EndoMatrix, Inc. (acquired by C.R. Bard in 1997.) Up until 1995, Josh was Founder and Manager of Pfizer’s Strategic Innovation Group. Josh holds over four dozen patents for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery and urology.
Josh received a Masters of Business Administration from Columbia University, a Doctor of Medicine degree from the New York University School of Medicine, and a Bachelor of Science in Mechanical Engineering from the Massachusetts Institute of Technology.
Effective June 1, 2004, Kevin Sidow began his role as President and Chief Executive Officer for St. Francis Medical Technologies, Inc. Prior to joining SFMT, Kevin was the Worldwide President of DePuy Inc. As former Worldwide President of DePuy; Kevin oversaw the global orthopedic, spine, trauma, and sports medicine businesses and has over 20 years of orthopedic medical device experience. His responsibilities included the combined worldwide reconstructive business (hips, knee, extremities, operating room products, ACE and casting), Spine, Mitek (sports medicine) and Biologics with annual revenue responsibility of over $3 billion.
Kevin joined DePuy in March of 1998 as Midwest Area Vice President. He was promoted to Vice President, Sales, for DePuy Orthopaedics in October 1999 where he contributed significantly to the integration of the joints sales force while achieving record sales levels. He was promoted to President of DePuy Orthopaedics in August 2000. In April 2001, he was promoted to Worldwide President, DePuy Orthopaedics, ACE and Casting. In September 2003 he advanced to the position of Worldwide President, DePuy Inc. in addition to becoming a member of the MD&D Group Operating Committee. Prior to joining DePuy, Kevin was with Howmedica, then the orthopaedic division of Pfizer.
SFMT’s first product, the X STOP® Interspinous Process Decompression (IPD) System for treatment of lumbar spinal stenosis, provides a minimally invasive alternative for spinal decompression. Founded in 1997, St. Francis Medical Technologies is a privately held company focused on developing innovative treatments for patients suffering from degenerative spinal disorders. Headquartered in Alameda, CA, the Company has raised a total of $28 million in venture capital to date.
In January 2007, St. Francis Medical Technologies, Inc. was sold for $725 million to Kyphon Inc.
Brian joined Covidien in March 2010 as the VP&GM of Vascular Therapies. Following the acquisition of ev3 in July of 2010 Brian took responsibility for the Global Peripheral Vascular Business. Over the last 3.5 years Covidien's Peripheral Vascular Business has grown from $700m to $1.2b through five strategic acquisitions, significant improvement in product development processes and focus on globalizing portfolio. The vision of the Peripheral Vascular Business is to be the clear first choice for customers, patients and employees by delivering breakthrough innovation for the treatment of peripheral vascular disease worldwide through customer collaboration, speed of innovation and business development. Brian has 24 years of experience in the medical industry and previously held the position of Vice President, U.S. Sales for Medtronic Vascular. Brian graduated with Bachelor Degree in Economics from the University of Connecticuts.